Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 6
2019 3
2020 16
2021 16
2022 20
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon EB, Felip E, Paz-Ares L, Mornex F, Vokes EE, Adjei AA, Robinson C, Sato M, Vugmeyster Y, Machl A, Audhuy F, Chaudhary S, Barlesi F. Cho BC, et al. J Thorac Oncol. 2023 Dec;18(12):1731-1742. doi: 10.1016/j.jtho.2023.08.018. Epub 2023 Aug 18. J Thorac Oncol. 2023. PMID: 37597750 Free article. Clinical Trial.
METHODS: This adaptive phase 3 trial (NCT03631706) compared the efficacy and safety of bintrafusp alfa versus pembrolizumab as first-line treatment in patients with PD-L1-high advanced NSCLC. ...RESULTS: Patients (N = 304) were randomized one-to-one to receive eithe …
METHODS: This adaptive phase 3 trial (NCT03631706) compared the efficacy and safety of bintrafusp alfa versus pembrolizumab as …
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Yoo C, Javle MM, Verdaguer Mata H, de Braud F, Trojan J, Raoul JL, Kim JW, Ueno M, Lee CK, Hijioka S, Cubillo A, Furuse J, Azad N, Sato M, Vugmeyster Y, Machl A, Bajars M, Bridgewater J, Oh DY, Borad MJ. Yoo C, et al. Hepatology. 2023 Sep 1;78(3):758-770. doi: 10.1097/HEP.0000000000000365. Epub 2023 Apr 1. Hepatology. 2023. PMID: 36999533 Free PMC article. Clinical Trial.
BACKGROUND AND AIMS: Biliary tract cancers are rare, heterogeneous cancers with poor prognoses. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-betaRII (a TGF-beta "trap") fused to a human IgG1 monoclonal ant …
BACKGROUND AND AIMS: Biliary tract cancers are rare, heterogeneous cancers with poor prognoses. Bintrafusp alfa, a first-in-cl …
Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFbetaRII agent: Current status.
Gameiro SR, Strauss J, Gulley JL, Schlom J. Gameiro SR, et al. Exp Biol Med (Maywood). 2022 Jul;247(13):1124-1134. doi: 10.1177/15353702221089910. Epub 2022 Apr 27. Exp Biol Med (Maywood). 2022. PMID: 35473390 Free PMC article. Review.
Bintrafusp alfa (anti-PD-L1/TGFbetaRII) is a first-in-class bifunctional agent designed to act both as a checkpoint inhibitor and as a "trap" for TGFbeta in the tumor microenvironment (TME). This article is designed to review the preclinical studies interrogating th …
Bintrafusp alfa (anti-PD-L1/TGFbetaRII) is a first-in-class bifunctional agent designed to act both as a checkpoint inhibitor …
Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer.
Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, Sinkoe A, Papanicolau-Sengos A, Lee CC, Marte JL, Turkbey E, Mydlarz W, Joshi A, London NR Jr, Pierce M, Taylor R, Hong S, Nguyen A, Soon-Shiong P, Schlom J, Gulley JL, Allen CT. Redman JM, et al. J Clin Invest. 2022 Sep 15;132(18):e161400. doi: 10.1172/JCI161400. J Clin Invest. 2022. PMID: 35727629 Free PMC article. Clinical Trial.
BACKGROUNDHead and neck squamous cell carcinoma not associated with HPV (HPV-unrelated HNSCC) is associated with a high rate of recurrence and poor survival.METHODSWe conducted a clinical trial in 14 patients with newly diagnosed HPV-unrelated HNSCC to evaluate the safety and eff …
BACKGROUNDHead and neck squamous cell carcinoma not associated with HPV (HPV-unrelated HNSCC) is associated with a high rate of recurrence a …
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-beta and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
Barlesi F, Isambert N, Felip E, Cho BC, Lee DH, Peguero J, Jerusalem G, Penel N, Saada-Bouzid E, Garrido P, Helwig C, Locke G, Ojalvo LS, Gulley JL. Barlesi F, et al. Oncologist. 2023 Mar 17;28(3):258-267. doi: 10.1093/oncolo/oyac253. Oncologist. 2023. PMID: 36571770 Free PMC article.
BACKGROUND: Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transforming growth factor beta receptor II (a TGF-beta "trap") fused to a human immunoglobulin G1 monoclonal antibody blocking programmed cell death …
BACKGROUND: Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transformi …
Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer.
Cheng B, Ding K, Chen P, Ji J, Luo T, Guo X, Qiu W, Ma C, Meng X, Wang J, Yu J, Liu Y. Cheng B, et al. Cancer Commun (Lond). 2022 Jan;42(1):17-36. doi: 10.1002/cac2.12244. Epub 2022 Jan 3. Cancer Commun (Lond). 2022. PMID: 34981670 Free PMC article.
BACKGROUND: Second-generation programmed cell death-protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, such as bintrafusp alfa (M7824), SHR-1701, and YM101, have been developed to simultaneously block PD-1/PD-L1 and transforming growth factor-beta/t …
BACKGROUND: Second-generation programmed cell death-protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, such as bintrafusp …
Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, Lan Y, Dussault I, Moustakas A. Gulley JL, et al. Mol Oncol. 2022 Jun;16(11):2117-2134. doi: 10.1002/1878-0261.13146. Epub 2022 Jan 4. Mol Oncol. 2022. PMID: 34854206 Free PMC article. Review.
Currently, the furthest developed dual-targeting agent is bintrafusp alfa. This drug is a first-in-class bifunctional fusion protein that consists of the extracellular domain of the TGF-betaRII receptor (a TGF-beta 'trap') fused to a human immunoglobulin G1 (IgG1) m …
Currently, the furthest developed dual-targeting agent is bintrafusp alfa. This drug is a first-in-class bifunctional fusion p …
Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial.
Chiang CL, Lam TC, Li JCB, Chan KSK, El Helali A, Lee YYP, Law LHT, Zheng D, Lo AWI, Kam NW, Li WS, Cheung AKW, Chow JCH, Chan SPC, Lai JWY, Lee SWM, Kong FS, Ng WT, Kwong DLW, Lee AWM. Chiang CL, et al. Lancet Reg Health West Pac. 2023 Sep 6;40:100898. doi: 10.1016/j.lanwpc.2023.100898. eCollection 2023 Nov. Lancet Reg Health West Pac. 2023. PMID: 37701718 Free PMC article.
BACKGROUND: The strategy of dual blockade of TGF-beta and PD-L1 pathways has not been previously tested in platinum-refractory recurrent or metastatic nasopharyngeal cancer (R/M NPC) patients. This study aimed to evaluate the safety and efficacy of bintrafusp alfa i …
BACKGROUND: The strategy of dual blockade of TGF-beta and PD-L1 pathways has not been previously tested in platinum-refractory recurrent or …
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-beta, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
Spira A, Wertheim MS, Kim EJ, Tan B, Lenz HJ, Nikolinakos P, Rich PL, Jehl G, Machl A, Ito R, Gulley JL, Kopetz S. Spira A, et al. Oncologist. 2023 Feb 8;28(2):e124-e127. doi: 10.1093/oncolo/oyac254. Oncologist. 2023. PMID: 36576431 Free PMC article. Clinical Trial.
Targeting transforming growth factor beta (TGF-beta) and programmed death ligand 1 pathways may enhance antitumor efficacy. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-beta receptor II (a TGF-beta "trap …
Targeting transforming growth factor beta (TGF-beta) and programmed death ligand 1 pathways may enhance antitumor efficacy. Bintrafusp …
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-beta and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
Khasraw M, Weller M, Lorente D, Kolibaba K, Lee CK, Gedye C, I de La Fuente M, Vicente D, Reardon DA, Gan HK, Scott AM, Dussault I, Helwig C, Ojalvo LS, Gourmelon C, Groves M. Khasraw M, et al. Neurooncol Adv. 2021 Apr 9;3(1):vdab058. doi: 10.1093/noajnl/vdab058. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34056607 Free PMC article.
METHODS: In this phase I, open-label expansion cohort (NCT02517398), patients with rGBM that progressed after radiotherapy plus temozolomide received bintrafusp alfa 1200 mg Q2W until disease progression, unacceptable toxicity, or trial withdrawal. ...CONCLUSIONS: T …
METHODS: In this phase I, open-label expansion cohort (NCT02517398), patients with rGBM that progressed after radiotherapy plus temozolomide …
73 results